Meropenem y ácido valproico: una asociación peligrosa

Eimil-Ortiz, M; Aguirre-Mollehuanca, D; Sierra-Limpo, A; Fontán-Tirado, C; Villar-Villar, ME.
Rev. neurol. (Ed. impr.) ; 46(2): 124-125, 16 ene., 2008.
Artículo en Es | IBECS (España) | ID: ibc-65966

Documentos relacionados

  1. Effect of a Declined Plasma Concentration of Valproic Acid Induced by Meropenem on the Antiepileptic Efficacy of Valproic Acid.
  2. Carnitine supplementation prevents carnitine deficiency caused by pivalate-conjugated antibiotics in patients with epilepsy prescribed valproate.
  3. Treatment of valproic acid overdose with meropenem in an epileptic patient.
  4. Value of Group Intervention on Prognosis of Quality of Life in Epileptic Patients Treated With Sodium Valproate and Lamotrigine.
  5. Effects of l-carnitine supplementation in patients with childhood-onset epilepsy prescribed valproate.
  6. Effects of sodium valproate and levetiracetam on posterior segment parameters in children with epilepsy.
  7. Lacosamide effects on placental carriers of essential compounds in comparison with valproate: Studies in perfused human placentas.
  8. Antibacterial and anti-inflammatory activity of valproic acid-pyrazole conjugates as a potential agent against periodontitis.
  9. The effect of anti-seizure medications on lipid values in adults with epilepsy.
  10. <i>CYP3A5</i> genetic variants and their associations with carbamazepine and valproic acid response in Malaysian epileptic patients.